Related Experiment Video
Updated: Apr 27, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.6K
The potential for renoprotection with incretin-based drugs
Tetsuhiro Tanaka1, Yoshiki Higashijima1, Takehiko Wada1
1Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Kidney International
|July 10, 2014
Summary
Incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, show promise in treating type 2 diabetes and protecting against diabetic kidney disease (DKD) by reducing inflammation and improving kidney function.
Area of Science:
- Endocrinology
- Nephrology
- Pharmacology
Background:
- Incretin-based drugs, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, are standard treatments for type 2 diabetes.
- Beyond glycemic control, incretins possess extrapancreatic functions with potential benefits for diabetic kidney disease (DKD).
Purpose of the Study:
- To review recent findings on the efficacy of incretin-based therapies in managing DKD and its complications.
- To explore the mechanisms by which incretins exert protective effects on the kidneys in diabetic models.
Main Methods:
- Review of experimental studies and clinical evidence on incretin-based therapies in DKD.
- Analysis of the molecular pathways involved in incretin action on renal and vascular tissues.
Main Results:
- Incretins protect the vascular endothelium by reducing oxidative stress and inflammation, leading to decreased albuminuria and glomerular sclerosis.
- GLP-1 receptor agonists and DPP-4 inhibitors may lower blood pressure through effects on sodium excretion and diuresis.
- DPP-4 inhibitors' effects may involve GLP-1 signaling and other substrates like brain natriuretic peptide.
Conclusions:
- Incretin-based therapies offer a promising strategy for ameliorating DKD and its associated complications.
- Further research is warranted to fully elucidate the pleiotropic effects of incretins in kidney protection.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K